RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
TOT BIOPHARM International Co Stock

TOT BIOPHARM International Co Revenue 2024

TOT BIOPHARM International Co Revenue

1.12 B CNY

Ticker

1875.HK

ISIN

HK0000545266

In 2024, TOT BIOPHARM International Co's sales reached 1.12 B CNY, a 42.96% difference from the 780.63 M CNY sales recorded in the previous year.

The TOT BIOPHARM International Co Revenue history

YEARREVENUE (undefined CNY)GROSS MARGIN (%)
2026e1.6534,85
2025e1.4140,82
2024e1.1251,43
20230.7873,53
20220.4483,82
20210.0836,00
20200.0269,05
20190.0575,02
20180.0484,75
20170.0591,78

TOT BIOPHARM International Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into TOT BIOPHARM International Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by TOT BIOPHARM International Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects TOT BIOPHARM International Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of TOT BIOPHARM International Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into TOT BIOPHARM International Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing TOT BIOPHARM International Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on TOT BIOPHARM International Co’s growth potential.

TOT BIOPHARM International Co Revenue, EBIT and net profit per share

DateTOT BIOPHARM International Co RevenueTOT BIOPHARM International Co EBITTOT BIOPHARM International Co Net Income
2026e1.65 B undefined158.32 M undefined141.88 M undefined
2025e1.41 B undefined110.32 M undefined96.17 M undefined
2024e1.12 B undefined66.67 M undefined67.79 M undefined
2023780.63 M undefined-21.36 M undefined-37.76 M undefined
2022442.18 M undefined-38.33 M undefined-49.92 M undefined
202176.33 M undefined-255.46 M undefined-261.22 M undefined
202022.49 M undefined-291.78 M undefined-288.5 M undefined
201945.31 M undefined-271.5 M undefined-299.3 M undefined
201839.22 M undefined-236.61 M undefined-268.26 M undefined
201751.61 M undefined-106.35 M undefined-148.69 M undefined

TOT BIOPHARM International Co stock margins

The TOT BIOPHARM International Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of TOT BIOPHARM International Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for TOT BIOPHARM International Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the TOT BIOPHARM International Co's sales revenue. A higher gross margin percentage indicates that the TOT BIOPHARM International Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the TOT BIOPHARM International Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the TOT BIOPHARM International Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the TOT BIOPHARM International Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the TOT BIOPHARM International Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the TOT BIOPHARM International Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

TOT BIOPHARM International Co Margin History

TOT BIOPHARM International Co Gross marginTOT BIOPHARM International Co Profit marginTOT BIOPHARM International Co EBIT marginTOT BIOPHARM International Co Profit margin
2026e73.53 %9.61 %8.61 %
2025e73.53 %7.85 %6.84 %
2024e73.53 %5.97 %6.07 %
202373.53 %-2.74 %-4.84 %
202283.82 %-8.67 %-11.29 %
202136 %-334.7 %-342.24 %
202069.05 %-1,297.33 %-1,282.73 %
201975.02 %-599.23 %-660.59 %
201884.75 %-603.3 %-684.01 %
201791.78 %-206.07 %-288.11 %

TOT BIOPHARM International Co Aktienanalyse

What does TOT BIOPHARM International Co do?

TOT BIOPHARM International Co Ltd is a global biotechnology company based in Hong Kong. It was founded in 2005 and has since become a major player in the biopharmaceutical industry. The company's goal is to contribute to the improvement of medical care through innovative research and development of biological drugs. TOT BIOPHARM's business activities include pharmaceutical development, clinical research, and production of biological drugs. It serves various sectors, including cancer, immunology, ophthalmology, and vaccines. TOT BIOPHARM is strongly committed to the development of biopharmaceuticals and aims to be a leader in this field. One important focus of TOT BIOPHARM is the research of cancer drugs. The company has several drugs in its oncology pipeline, including a treatment for lung cancer called "Ponatinib". Additionally, TOT BIOPHARM has introduced a range of immuno-oncology therapies that can be used to treat various types of cancer. In the field of immunology, TOT BIOPHARM has launched several drugs for the treatment of autoimmune diseases, including "Natalizumab" for multiple sclerosis. Another important immunotherapy developed by TOT BIOPHARM is "Eculizumab," which is used to treat two rare blood disorders. In ophthalmology, TOT BIOPHARM is developing a new drug for the treatment of wet age-related macular degeneration (AMD). The drug is being tested in a Phase III clinical trial and has the potential to become the first biopharmaceutical for the treatment of AMD. Furthermore, TOT BIOPHARM has also developed vaccines, including a vaccine against the Japanese encephalitis virus (JEV) and a vaccine against enterovirus 71 (EV71). Both vaccines have been approved in China and are in high demand. TOT BIOPHARM's business model focuses on building a pipeline of innovative biopharmaceuticals that meet the needs of patients. The company operates a comprehensive research and development infrastructure that helps discover and develop new drug candidates. TOT BIOPHARM collaborates with universities, government agencies, and other business partners to accelerate its research and development and strengthen its market position. In addition, TOT BIOPHARM has a strong presence in the Chinese market for biopharmaceuticals. The company has a state-approved clinical research facility with over 1,000 employees in China and collaborates with leading Chinese hospitals and specialty clinics. This has given TOT BIOPHARM a preferred position in the Chinese market for biopharmaceuticals, and the company aims to expand its presence in other markets worldwide. Overall, TOT BIOPHARM International Co Ltd has built an impressive portfolio of biopharmaceuticals in recent years and is expected to continue to play a significant role in the biopharmaceutical industry. With a clear focus on research and development and a growing market position in China and other countries, the company is well-positioned to expand its business activities and strengthen its presence in the global market. TOT BIOPHARM International Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding TOT BIOPHARM International Co's Sales Figures

The sales figures of TOT BIOPHARM International Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing TOT BIOPHARM International Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize TOT BIOPHARM International Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in TOT BIOPHARM International Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about TOT BIOPHARM International Co stock

How much revenue did TOT BIOPHARM International Co generate this year?

TOT BIOPHARM International Co has achieved a revenue of 1.12 B CNY this year.

How much was the turnover of the company TOT BIOPHARM International Co compared to the previous year?

The revenue of TOT BIOPHARM International Co has increased by 42.96% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of TOT BIOPHARM International Co?

The revenue of TOT BIOPHARM International Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of TOT BIOPHARM International Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of TOT BIOPHARM International Co so important for investors?

The revenue of TOT BIOPHARM International Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does TOT BIOPHARM International Co pay?

Over the past 12 months, TOT BIOPHARM International Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TOT BIOPHARM International Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of TOT BIOPHARM International Co?

The current dividend yield of TOT BIOPHARM International Co is .

When does TOT BIOPHARM International Co pay dividends?

TOT BIOPHARM International Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TOT BIOPHARM International Co?

TOT BIOPHARM International Co paid dividends every year for the past 0 years.

What is the dividend of TOT BIOPHARM International Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is TOT BIOPHARM International Co located?

TOT BIOPHARM International Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von TOT BIOPHARM International Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TOT BIOPHARM International Co from 11/19/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did TOT BIOPHARM International Co pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of TOT BIOPHARM International Co in the year 2023?

In the year 2023, TOT BIOPHARM International Co distributed 0 CNY as dividends.

In which currency does TOT BIOPHARM International Co pay out the dividend?

The dividends of TOT BIOPHARM International Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von TOT BIOPHARM International Co

Our stock analysis for TOT BIOPHARM International Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TOT BIOPHARM International Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.